title: Effects of CD3McAb and rhIL-2 activated bone marrow on the killing and purging of leukemia cells.
abstract: We investigated the roles of CD3McAb and rhIL-2 activated bone marrow in the killing and purging of leukemia cells. Cytotoxicity of activated bone marrow was detected with MTT assay. CFU-GM level in activated bone marrow and the destruction of leukemia cells were measured using the semi-solid cell culture. Immune activation markers in activated bone marrow were detected by indirect immunofluorescence assay. Bone marrow activated by CD3McAb and rhIL-2 displayed significantly upregulated the killing and purging abilities on the leukemia cell line K562 and HL-60. Such effects were superior to that of bone marrow activated by rhIL-2 or CD3McAb alone (P < 0.05, P < 0.01). Activation by rhIL-2 and (or) CD3McAb exerted no obvious influence on CFU-GM level in bone marrow. Compared with bone marrow activated by rhIL-2 or CD3McAb alone, the synergistic effect of both CD3McAb+ and hIL-2 caused significant increase of CD3(+), CD8(+), CD19(+), CD25(+), CD38(+), and CD56(+) levels. Our study indicates that CD3McAb enhanced the killing and purging effects of rhIL-2 activated bone marrow on leukemia cells.
authors.affiliation: Institute of hematological research, Shaanxi Provincial People's Hospital, Xi'an, China.
authors.forename: X C
authors.initials: XC
authors.lastname: Wei
authors.affiliation: Institute of hematological research, Shaanxi Provincial People's Hospital, Xi'an, China.
authors.forename: D D
authors.initials: DD
authors.lastname: Yang
authors.affiliation: Institute of hematological research, Shaanxi Provincial People's Hospital, Xi'an, China.
authors.forename: X R
authors.initials: XR
authors.lastname: Han
authors.affiliation: Institute of hematological research, Shaanxi Provincial People's Hospital, Xi'an, China.
authors.forename: Y A
authors.initials: YA
authors.lastname: Zhao
authors.affiliation: Institute of hematological research, Shaanxi Provincial People's Hospital, Xi'an, China.
authors.forename: Y C
authors.initials: YC
authors.lastname: Li
authors.affiliation: Institute of hematological research, Shaanxi Provincial People's Hospital, Xi'an, China.
authors.forename: L J
authors.initials: LJ
authors.lastname: Zhang
authors.affiliation: Institute of hematological research, Shaanxi Provincial People's Hospital, Xi'an, China.
authors.forename: J J
authors.initials: JJ
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology*; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D016465:Bone Marrow Purging / Q000379:methods; D016026:Bone Marrow Transplantation; D017252:CD3 Complex / Q000276:immunology / Q000378:metabolism; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003114:Colony-Forming Units Assay; D005260:Female; D055014:Granulocyte-Macrophage Progenitor Cells; D018922:HL-60 Cells; D006801:Humans; D016130:Immunophenotyping; D007376:Interleukin-2 / Q000494:pharmacology*; D020014:K562 Cells; D007938:Leukemia / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D007376:Interleukin-2